NuGenerex Immuno-Oncology, Inc.
NUGX
NuGenerex Immuno-Oncology, Inc. is an oncology firm committed to treating... NuGenerex Immuno-Oncology, Inc. is an oncology firm committed to treating cancer through the strategic modulation of the immune system. The company's development pipeline includes a range of immunotherapeutic products and vaccines. Notably, it is advancing AE37, a peptide immunotherapeutic vaccine, which is currently undergoing Phase II clinical studies for metastatic triple-negative breast cancer. Founded in 1993 and headquartered in Miramar, Florida, the entity was formerly named Antigen Express, Inc. NuGenerex Immuno-Oncology, Inc. operates as a subsidiary of Generex Biotechnology Corporation.
